This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Epstein, S. S. Articles by Mantel, N. Search for Related Content PubMed PubMed Citation Articles by Epstein, S. S. Articles by Mantel, N.

Hepatocarcinogenicity of Griseofulvin following Parenteral Administration to Infant Mice¹

^[1] Laboratories of Carcinogenesis and Histology, The Children's Cancer Research Foundation, and Department of Pathology, Harvard Medical School, at The Children's Hospital, Boston, Massachusetts 02115
^[2] Biometry Branch, National Cancer Institute, Bethesda, Maryland 20014

Random-bred infant Swiss mice were injected subcutaneously with suspensions of griseofulvin in tricaprylin according to various dosage schedules. Doses of griseofulvin in excess of 0.25 mg on Day 1 of life produced acute toxicity. Following a total dosage of 3.0 mg in infant mice, 0.5, 0.5, 1.0, and 1.0 mg at ages of 1, 7, 14, and 21 days, respectively, a high incidence of hepatomata, in 44% of 16 male mice alive at 49 weeks, developed in comparison with solvent controls, 8% of 48 males.

¹ Supported by USPHS Research Grant # C-6516 (to The Children's Cancer Research Foundation) from the National Cancer Institute.

Received 3/30/67. Accepted 6/30/67.